$BVS Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.17 up 13.33% YoY
• Reported revenue of $142.44M up 2.73% YoY
• Bioventus reaffirmed FY2026 Adjusted EPS guidance of $0.75 to $0.79 per diluted share, with net sales guidance of $590M to $595M and Adjusted Cash from Operations of $84M to $89M.